Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Gains from Investment Securities (2016 - 2025)

Tg Therapeutics has reported Gains from Investment Securities over the past 10 years, most recently at -$20.0 million for Q4 2025.

  • Quarterly results put Gains from Investment Securities at -$20.0 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was -$20.5 million (down 24936.59% YoY), and the annual figure for FY2025 was $4.2 million, up 5506.42%.
  • Gains from Investment Securities for Q4 2025 was -$20.0 million at Tg Therapeutics, down from $4.4 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for TGTX hit a ceiling of $5.2 million in Q3 2022 and a floor of -$20.0 million in Q4 2025.
  • Median Gains from Investment Securities over the past 5 years was $192500.0 (2023), compared with a mean of -$577252.6.
  • Biggest five-year swings in Gains from Investment Securities: plummeted 947.87% in 2021 and later soared 42872.88% in 2022.
  • Tg Therapeutics' Gains from Investment Securities stood at -$8.1 million in 2021, then surged by 72.94% to -$2.2 million in 2022, then soared by 33.2% to -$1.5 million in 2023, then soared by 161.1% to $900000.0 in 2024, then crashed by 2317.44% to -$20.0 million in 2025.
  • The last three reported values for Gains from Investment Securities were -$20.0 million (Q4 2025), $4.4 million (Q3 2025), and $56250.0 (Q2 2025) per Business Quant data.